| 前收盘价格 | 577.89 |
| 收盘价格 | 573.28 |
| 成交量 | 425,164 |
| 平均成交量 (3个月) | 399,290 |
| 市值 | 35,542,499,328 |
| 市盈率 (P/E TTM) | 33.55 |
| 预期市盈率 (P/E Forward) | 59.17 |
| 价格/销量 (P/S) | 14.96 |
| 股市价格/股市净资产 (P/B) | 6.42 |
| 52周波幅 | |
| 利润日期 | 31 Jul 2025 |
| 营业毛利率 | 40.26% |
| 营业利益率 (TTM) | 17.50% |
| 稀释每股收益 (EPS TTM) | 16.41 |
| 季度收入增长率 (YOY) | 95.70% |
| 总债务/股东权益 (D/E MRQ) | 0.71% |
| 流动比率 (MRQ) | 7.29 |
| 营业现金流 (OCF TTM) | -82.75 M |
| 杠杆自由现金流 (LFCF TTM) | -143.39 M |
| 资产报酬率 (ROA TTM) | -0.21% |
| 股东权益报酬率 (ROE TTM) | 17.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | argenx SE | 看涨 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.38 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 机构持股比例 | 55.51% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 1,065.00 (Guggenheim, 93.21%) | 购买 |
| 中 | 717.50 (30.17%) | |
| 低 | 680.00 (Baird, 23.36%) | 购买 |
| 平均值 | 781.83 (41.84%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 556.89 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Jun 2025 | 720.00 (30.62%) | 购买 | 574.96 |
| 10 Jun 2025 | 720.00 (30.62%) | 购买 | 575.46 | |
| Wedbush | 11 Jun 2025 | 715.00 (29.71%) | 购买 | 574.96 |
| 16 Apr 2025 | 715.00 (29.71%) | 购买 | 587.59 | |
| Baird | 13 May 2025 | 680.00 (23.36%) | 购买 | 542.47 |
| Citigroup | 09 May 2025 | 803.00 (45.68%) | 购买 | 549.65 |
| 17 Apr 2025 | 796.00 (44.41%) | 购买 | 596.20 | |
| Guggenheim | 09 May 2025 | 1,065.00 (93.21%) | 购买 | 549.65 |
| Oppenheimer | 09 May 2025 | 708.00 (28.44%) | 购买 | 549.65 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合